Adult: 10-20 mg 4 times daily for 1-2 days if oral therapy is temporarily impractical.
Oral Gastrointestinal tract spasm
Adult: 10-20 mg tid. Dose is individualised according to patient needs. Dosing recommendations may vary among individual products and between countries (refer to specific product guidelines). Child: 6 months to <2 years 5-10 mg 3-4 times daily. 2-12 years 10 mg tid. >12 years Same as adult dose. Dosing recommendations may vary among individual products and between countries (refer to specific product guidelines).
May be taken with or without food.
Obstructive disease of the gastrointestinal tract, reflux oesophagitis, severe ulcerative colitis, unstable CV status in acute haemorrhage, glaucoma, obstructive uropathy, myasthenia gravis, salmonella dysentery. Infants <6 months. Lactation.
Patient with coronary artery disease, heart failure, hypertension, tachyarrhythmia (e.g. thyrotoxicosis), hyperthyroidism, autonomic neuropathy, known or suspected prostatic hyperplasia, mild to moderate ulcerative colitis, altered physical or mental abilities, fever. Patients undergoing cardiac surgery. Presence of increased environmental temperature (e.g. hot weather, exercise). Renal and hepatic impairment. Children and elderly. Pregnancy.
Significant: Drowsiness, blurred vision, diarrhoea, heat prostration (in increased environmental temperature), psychosis and delirium (especially elderly and mentally ill patients). Cardiac disorders: Palpitations, tachyarrhythmia. Eye disorders: Mydriasis, cycloplegia, photophobia. Gastrointestinal disorders: Dry mouth, thirst, constipation, nausea, vomiting, abdominal pain, abdominal distension, dyspepsia. General disorders and admin site conditions: Fatigue, asthenia. Metabolism and nutrition disorders: Anorexia. Nervous system disorders: Dizziness, sedation, headache, nervousness. Psychiatric disorders: Insomnia. Renal and urinary disorders: Dysuria. Reproductive system and breast disorders: Suppressed lactation. Respiratory, thoracic and mediastinal disorders: Dyspnoea, nasal congestion, reduced bronchial secretions. Skin and subcutaneous tissue disorders: Rash, allergic dermatitis, erythema. Vascular disorders: Flushing.
This drug may cause drowsiness or blurred vision, if affected, do not drive or operate machinery.
Monitor urinary output, anticholinergic effects, and gastrointestinal symptoms.
Symptoms: Headache, dizziness, nausea, vomiting, dry mouth, difficulty swallowing, dilated pupils, blurred vision; hot, dry skin; CNS stimulation, convulsion. Management: Symptomatic treatment. May perform gastric lavage or administer emetics and activated charcoal. May administer sedatives (e.g. benzodiazepines, short-acting barbiturates) to manage overt signs of excitement. May use appropriate parenteral cholinergic agent as antidote.
Enhanced adverse effect with other anticholinergic agents (e.g. amantadine, quinidine, antihistamines, phenothiazine, benzodiazepines, MAOIs, meperidine, nitrates and nitrites, TCAs, sympathomimetic agents). May antagonize the effects of antiglaucoma agents. May diminish the therapeutic effect of gastrokinetic drugs (e.g. metoclopramide). Altered absorption with antacids.
Description: Dicycloverine, a tertiary amine antimuscarinic, relieves gastrointestinal smooth muscle spasm by blocking the action of acetylcholine at parasympathetic sites in the smooth muscle, CNS and secretory glands.
Synonym: dicyclomine. Onset: 1-2 hours. Duration: Up to 4 hours. Pharmacokinetics: Absorption: Rapid and well absorbed. Bioavailability: IM: Approx 2 times more bioavailable than oral administration. Time to peak plasma concentration: 60-90 minutes (oral). Distribution: Enters breast milk. Volume of distribution: 3.65 L/kg. Metabolism: Extensively metabolised. Excretion: Mainly via urine (80%, small amounts as unchanged drug); faeces (8%). Elimination half-life: Approx 1.8 hours (initial phase).
Store between 20-30°C. Cap/tab/oral solution: Protect from direct sunlight and excessive heat. Inj: Protect from freezing. Storage recommendations may vary among individual products (refer to specific product guidelines).